Brookline Capital initiated coverage on Icecure Medical with a new price target
$ICCM
Medical/Dental Instruments
Health Care
Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/2/2022 | $5.65 | Buy | Brookline Capital |
| 9/22/2021 | $14.50 | Buy | Alliance Global Partners |
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel, June 9, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application titled 'Cryogen Flow Control'. Once granted, the patent will be in effect until 2045. A patent has already been granted for this invention in
Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025. IceCure delivered its proposed post
CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is
Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025. IceCure delivered its proposed post
CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)
Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65
Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50
6-K - IceCure Medical Ltd. (0001584371) (Filer)
6-K - IceCure Medical Ltd. (0001584371) (Filer)
6-K - IceCure Medical Ltd. (0001584371) (Filer)
Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha
Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin
CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie